Fig. 5

Association of TASL mRNA expression with OS and clinicopathological parameters in cancer patients. A Forest plot of Hazard Ratios of TASL for 20 cancers in TCGA. B K-M curves for OS of LGG, LUAD, and SKCM patients grouped by high and low TASL expression. C TASL expression in LGG patients with different WHO grades, IDH mutation status, 1p/19q co-deletion status, and pathological types. TASL expression in LUAD (D) and SKCM (E) with different AJCC TNM stages and pathological stages (*P < 0.05; **P < 0.01; ***P < 0.001)